Uncover key drivers, emerging technologies, and competitive movements shaping the edema clinical trials market from 2026–2035 with trusted insights from The Business Research Company
What is the estimated market size of the Edema Clinical Trials Market by the end of 2030?
The market size for edema clinical trials has experienced robust growth in recent years. It is forecast to increase from $1.23 billion in 2025 to $1.34 billion in 2026, registering a compound annual growth rate (CAGR) of 8.8%. This historical expansion can be attributed to the rising prevalence of cardiovascular and renal disorders, the development of clinical research infrastructure, increased pharmaceutical R&D investments, the growth in investigator-led trials, and enhancements in clinical trial management systems.
The edema clinical trials market is anticipated to experience substantial expansion over the coming years, with projections indicating it will reach $1.85 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.5%. This market growth during the forecast period is primarily driven by escalating demand for targeted edema treatments, the increasing adoption of decentralized clinical trial methodologies, the broadening scope of precision medicine strategies, the enhanced integration of digital tools for data capture, and augmented regulatory backing for novel trial designs. Key developments expected during this period encompass the growing application of AI for patient recruitment, the increased embrace of adaptive trial protocols, a stronger emphasis on biomarker-based outcomes, the proliferation of multi-center global studies, and a greater focus on incorporating real-world evidence.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28211&type=smp
What Drivers Are Shaping Future Opportunities In The Edema Clinical Trials Market?
The rising occurrence of lifestyle-related diseases is anticipated to boost the expansion of the edema clinical trials market going forward. These conditions are illnesses that stem from daily behaviors and choices, including a sedentary lifestyle, unhealthy eating habits, and substance use. The prevalence of lifestyle-related diseases is increasing due to poor dietary practices, as the widespread consumption of processed and high-calorie foods contributes to conditions such as obesity, diabetes, and cardiovascular problems. Edema clinical trials provide support for lifestyle-related diseases by developing and evaluating treatments that address fluid buildup linked to obesity, diabetes, and cardiovascular conditions. For instance, in March 2024, data from the Office for Health Improvement & Disparities, a UK-based government department, indicated that between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, and for type 2 diabetes, it increased by 21%. Furthermore, the percentage achieving target HbA1c levels rose to 37.9%, representing the highest value ever reported by the National Diabetes Audit (NDA). Therefore, the growing incidence of lifestyle-related diseases is driving the growth of the edema clinical trials market.
Which Segments Are Gaining Traction In The Edema Clinical Trials Market?
The edema clinical trials market covered in this report is segmented –
1) By Phase: Phase I, Phase II, Phase III, Phase IV
2) By Type: Peripheral Edema, Pulmonary Edema, Cerebral Edema, Nephrotic Syndrome Edema
3) By Study Design: Interventional, Observational, Expanded Access
4) By Participant: Pediatrics, Adults, Geriatrics
5) By End User: Pharmaceutical Companies, Research Institutions, Contract Research Organizations (CROs), Academic Research Centers
Subsegments:
1) By Phase I: Single Ascending Dose, Multiple Ascending Dose
2) By Phase II: Proof of Concept, Phase IIb Dose Optimization
3) By Phase III: Pivotal Efficacy Trials, Comparative Trials
4) By Phase IV: Post-Marketing Surveillance, Long-Term Safety Studies
Which Trends Are Influencing The Performance And Direction Of The Edema Clinical Trials Market?
Major companies operating in the edema clinical trials market are increasingly prioritizing the development of innovative solutions, such as refillable ocular implants, to enhance treatment efficacy and patient adherence in managing chronic eye conditions linked to edema. A refillable ocular implant functions as a medical device inserted into the eye, capable of continuously dispensing medication over an extended duration and facilitating periodic drug refills without necessitating the implant’s removal or replacement, thereby ensuring sustained treatment for ongoing eye conditions like macular edema. For instance, in February 2025, Roche Holding AG, a Switzerland-based pharmaceutical company, received FDA approval for Susvimo, establishing it as the first and sole continuous delivery treatment for diabetic macular edema (DME) and diabetic retinopathy (DR), both significant contributors to diabetes-related blindness, offering an alternative to frequent eye injections with considerably fewer annual treatments. This groundbreaking approval signifies a substantial advancement in ophthalmic care, as Susvimo’s implantable delivery system is designed to improve patient compliance and alleviate the treatment burden, potentially leading to improved long-term outcomes for individuals living with these chronic eye conditions.
Who Are The Core Companies Influencing Trends In The Edema Clinical Trials Market?
Major companies operating in the edema clinical trials market are Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, CSL Limited, Regeneron Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Genentech Inc., Ionis Pharmaceuticals Inc., ANI Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Tactile Medical, REGENXBIO Inc., Koya Medical Inc., KalVista Pharmaceuticals Inc., Kodiak Sciences Inc., Pharvaris B.V., Oxurion NV, Outlook Therapeutics Inc., Adverum Biotechnologies Inc., Oculis Holding AG
Access The Complete Report For Deeper Market Insights:
https://www.thebusinessresearchcompany.com/report/edema-clinical-trials-global-market-report
Which Geographic Areas Are Emerging As Strong Markets For The Edema Clinical Trials Market?
North America was the largest region in the edema clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the edema clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Edema Clinical Trials Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=28211&type=smp
Browse Through More Reports Similar to the Global Edema Clinical Trials Market 2026, By The Business Research Company
Virtual Clinical Trials Market Report 2026
https://www.thebusinessresearchcompany.com/report/virtual-clinical-trials-global-market-report
Cardiovascular Clinical Trials Market Report 2026
Healthcare Edi Market Report 2026
https://www.thebusinessresearchcompany.com/report/healthcare-edi-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model